Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Ablation & Embolization
Hifu for prostate cancer
High-intensity focused ultrasound (HIFU) for prostate cancer destroys targeted prostate tumours using focused acoustic heat while sparing healthy surrounding nerves and urinary sphincters. This guide outlines how focal HIFU works, what clinical evidence confirms, realistic recovery milestones with a catheter, candidate criteria, comparative costs in Turkey against the UK, US and Germany, and vital safety considerations.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Ablation & Embolization
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for HIFU for Prostate Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
HIFU for prostate cancer in Turkey: what it is and how focal ablation works
HIFU for prostate cancer (high-intensity focused ultrasound) is an organ-sparing ablative therapy designed to destroy cancerous lesions within the prostate without surgical incisions. An endorectal probe delivers focused sound waves that converge at pinpoint coordinates inside the gland. At this focal zone, the acoustic energy produces rapid heat and mechanical cavitation, causing instant coagulative necrosis of malignant cells while leaving the surrounding healthy tissue undamaged. Because the ultrasound beams pass harmlessly through intervening rectal and pelvic structures, treatment focuses strictly on the tumour.
Over the past decade, high-intensity focused ultrasound has developed from an experimental modality into an established focal therapy for men with localised prostate cancer. Rather than removing the entire prostate gland and risking severe nerve damage, urologists use advanced multiparametric magnetic resonance imaging (mpMRI) fused with real-time ultrasound to map and ablate only the diseased zone. When exploring options, patients frequently ask what is hifu for prostate cancer and how it compares with traditional surgery. Choosing hifu for prostate cancer Turkey allows international patients to access modern robotic ablation platforms with structured clinical pathways. For an overview of care pathways, explore our guide to oncology treatments in Turkey.
How does the high-intensity focused ultrasound procedure work?
The core mechanism of HIFU relies on precise acoustic physics rather than ionising radiation or scalpel excision. A computer-controlled transrectal transducer emits ultrasound waves at frequencies typically between 3 and 4 MHz. These waves pass through the rectal wall without causing injury because the energy density along the beam path remains low. However, when multiple ultrasound beams converge at the predetermined focal point within the prostate, energy concentrates dramatically.
Within seconds, tissue temperature at the focal zone rises to 65–85°C. This rapid thermal rise causes irreversible protein denaturation and instant coagulative necrosis of the targeted prostate tissue. In addition to thermal destruction, acoustic cavitation produces microscopic bubbles that oscillate and collapse, mechanically disrupting cancer cell membranes. Outside the 1–2 mm focal target, temperatures drop off sharply, which protects adjacent critical structures including the neurovascular bundles that control erectile function, the external urinary sphincter that maintains continence, and the rectal mucosal wall.
Does HIFU for prostate cancer actually work? What the clinical evidence shows
Clinical studies and international guidelines confirm that hifu for prostate cancer provides effective short-to-medium-term oncological control for well-selected patients. The National Institute for Health and Care Excellence (NICE) in the UK and the European Association of Urology (EAU) recognise HIFU as an established option for clinically localised, low- to intermediate-risk prostate cancer (Gleason 6 or Gleason 7 [3+4], corresponding to ISUP Grade Groups 1 and 2). It is also recognized as a salvage treatment for cancer recurrence following prior external beam radiotherapy.
When considering does hifu for prostate cancer work, patient selection is crucial. For localised index lesions, published registry data show disease control rates comparable to surgery and radiotherapy over three to five years, while preserving urinary continence in over 95% of patients and erectile function in 70–85% of men who had normal function prior to treatment. However, an honest assessment must acknowledge limitations: comparative long-term data beyond ten to fifteen years are still maturing. Furthermore, because untreated prostate tissue remains in place, approximately 15–20% of patients may require repeat focal ablation or secondary therapy if new lesions arise. HIFU is not suitable for high-risk, locally advanced or metastatic prostate cancer.
HIFU for prostate cancer cost in Turkey compared with the UK, US and Germany
The figures below reflect approximate cost ranges for treatment packages across different countries. These ranges are provided for general comparison and do not represent specific hospital quotes, as pricing depends on tumour location, gland volume, equipment type and clinical length of stay.
| Country | Approximate cost range |
|---|---|
| Turkey | €5,500 – €12,000 |
| United Kingdom | €10,000 – €22,000 |
| United States | €18,000 – €35,000 |
| Germany | €9,000 – €18,000 |
When evaluating the overall hifu for prostate cancer cost and comparing quotes, patients should review what is covered. Variables influencing the final hifu for prostate cancer price include whether treatment is targeted focal ablation, hemi-ablation or subtotal ablation; the specific robotic system used (such as Sonablate or Focal One); pre-operative imaging fusion reviews; anaesthetist fees; and the duration of post-operative observation. In Turkey, comprehensive treatment packages typically include the procedure, operating theatre fees, one or two hospital nights, pathology reviews, catheter removal materials, medications and airport transfers. Patients can request a detailed plan via our free quote form.
HIFU vs radical prostatectomy, radiotherapy and other focal therapies
Prostate cancer management has moved away from a single approach for all patients. Choosing between treatments involves balancing cancer control against the preservation of sexual potency and urinary continence. Radical prostatectomy removes the entire prostate gland, providing comprehensive pathology but carrying higher risks of permanent urinary leakage and erectile dysfunction. External beam radiotherapy treats the gland without surgery, but radiation proctitis, cystitis and gradual erectile decline remain concerns.
| Treatment approach | Suited to | Typical clinical trade-offs |
|---|---|---|
| HIFU (focal or hemi-ablation) | Organ-confined, low-to-intermediate risk unifocal or unilateral tumours | High preservation of continence and erectile function; requires ongoing PSA and MRI surveillance |
| Robotic radical prostatectomy | Localised or locally advanced cancer where complete gland excision is preferred | Definitive pathological specimen; higher risk of post-operative incontinence and erectile dysfunction |
| External beam radiotherapy | Localised or locally advanced disease, frequently combined with hormone therapy | Non-surgical; potential for radiation proctitis, cystitis and gradual erectile decline over several years |
| Active surveillance | Very low-risk, small-volume Gleason 6 disease with low baseline PSA | Avoids immediate treatment side effects; requires frequent repeat biopsies, PSA tests and scans |
Alongside thermal techniques like radiofrequency ablation and cryotherapy, HIFU focuses acoustic energy without inserting needles through the perineum into the prostate. This non-invasive delivery reduces post-procedure perineal hematomas and infection risks.
Who is a suitable candidate for HIFU prostate treatment, and who is not?
Candidate selection determines the success of hifu prostate cancer treatment. Good candidates meet specific clinical and radiological criteria:
- Biopsy-confirmed adenocarcinoma of the prostate with clinical stage T1c, T2a, or T2b (organ-confined disease).
- Low- to intermediate-risk disease: Gleason score 6 (3+3) or Gleason score 7 (3+4), corresponding to ISUP Grade Groups 1 and 2.
- Serum PSA levels generally below 10–15 ng/mL.
- A distinct index lesion clearly identified on multiparametric MRI (mpMRI) that matches biopsy findings.
- Men seeking an organ-sparing approach to protect urinary continence and erectile function.
- Patients with localized recurrence after primary radiation therapy who qualify for salvage HIFU.
Conversely, HIFU is not suitable for everyone. Poor candidates include men with cancer extending beyond the prostatic capsule (stage T3b or T4), known pelvic lymph node involvement, or distant bone metastases. Patients with extensive prostatic calcifications are generally ineligible because calcified stones reflect ultrasound waves and create acoustic shadows that prevent effective ablation. Large prostate glands (typically over 40–50 cm³) may require prior medical volume reduction or a transurethral resection before HIFU can be performed safely. Significant rectal scarring or active inflammatory bowel disease also prevents safe endorectal probe placement.
What happens during the HIFU procedure step by step?
The procedure is carried out in a hospital operating room and follows five structured steps:
- Preparation and anaesthesia: The patient completes a mild bowel preparation and enema the evening prior to ensure the rectum is clear. In theatre, general anaesthesia or spinal anaesthesia is administered so the pelvic floor remains completely still throughout the procedure.
- Positioning and probe insertion: The patient is positioned on their side or in the lithotomy position. A specialised endorectal probe encased in a silicone balloon is gently inserted into the rectum. Chilled, degassed liquid circulates continuously through the balloon to cool and protect the rectal wall during acoustic emissions.
- Imaging mapping and treatment planning: The urologist captures high-resolution 3D ultrasound images and fuses them with pre-operative mpMRI scans on the robotic console. The surgeon maps the precise boundary of the target lesion, adding a safe margin while marking preservation boundaries around the urinary sphincter and neurovascular bundles.
- Acoustic ablation: The computer-driven robotic arm directs the transducer to deliver ultrasound energy spot by spot. Each acoustic burst lasts several seconds, treating individual 2–3 mm tissue cylinders until the entire planned zone is ablated. Total ablation time typically lasts between 90 minutes and 3 hours depending on tumour volume.
- Catheter placement and recovery: At the conclusion of treatment, a temporary urethral Foley catheter or suprapubic catheter is inserted to ensure unobstructed bladder drainage while post-treatment swelling subsides. The patient is transferred to the recovery suite for monitoring.
Recovery timeline and catheter care after prostate HIFU
Understanding what hifu for prostate cancer recovery entails helps patients prepare practical arrangements for their stay and aftercare:
Days 1 to 2: Most patients stay in the hospital for one night following treatment. Walking gently around the ward is encouraged within hours of waking. Mild perineal tightness or dull pelvic aching is common and easily controlled with oral paracetamol or anti-inflammatory tablets.
Days 5 to 14: The urinary catheter remains in place while internal tissue swelling subsides. Patients are shown how to manage the leg bag and keep the catheter clean. A trial without catheter (TWOC) is conducted between day 5 and day 14 depending on the volume of tissue ablated. Once the catheter is removed and normal urination is verified, daily comfort improves significantly.
Weeks 2 to 4: Patients can resume sedentary desk work and routine social activities once the catheter is out. Light walking is beneficial, but vigorous workouts, heavy lifting, cycling, and sexual activity should be avoided for three to four weeks to allow internal healing.
Months 1 to 12: A baseline serum PSA test is performed at three months and repeated every three to six months. A post-treatment mpMRI is typically scheduled between six and twelve months to verify complete necrosis of the targeted lesion. You can read about how it works when arranging specialist medical travel and coordinated aftercare.
What results and PSA changes can you realistically expect?
Because prostate cancer treatment is oncological rather than cosmetic, results are measured through biochemical markers, radiological scans, and functional quality of life rather than visual before-and-after photographs.
Following focal HIFU, serum PSA levels drop significantly, typically reaching their lowest point (the PSA nadir) within three to six months. In successful focal ablation, PSA drops by roughly 70% to 90%, reflecting the destruction of the dominant cancer lesion while normal untreated prostate tissue continues producing low baseline PSA. Follow-up multiparametric MRI at six to twelve months should demonstrate absence of contrast enhancement in the ablated zone, confirming that the tumour tissue has been replaced by benign scar tissue.
From a functional perspective, preservation rates are favourable. Over 95% of patients maintain pad-free urinary continence because the external urinary sphincter is spared. For men with normal pre-operative sexual function, between 70% and 85% maintain functional erections, though temporary erectile softness can occur for several weeks due to local tissue inflammation. Realistic expectations require understanding that HIFU is an organ-preserving treatment: lifelong monitoring remains necessary to verify that untreated prostate zones remain healthy.
Potential risks, side effects and safety considerations
While HIFU is non-invasive and carries lower complication rates than radical surgery, every medical intervention carries risks. Professional guidelines from the European Association of Urology and NICE highlight several recognized side effects:
- Urinary retention: Post-treatment swelling of the prostate can temporarily obstruct urine flow. This is the primary reason a catheter is placed immediately after surgery until tissue swelling recedes.
- Transient urinary symptoms: Frequency, urgency, mild burning during urination, and passing small flecks of necrotic tissue or light blood can occur during the first few weeks after catheter removal.
- Urinary tract infection: Catheterisation and instrumentation carry a small risk of bacterial cystitis, which is managed with targeted antibiotics.
- Urethral stricture: Scar tissue narrowing the urethra or bladder neck occurs in approximately 2% to 5% of cases and can require minor endoscopic dilation.
- Erectile dysfunction: Although significantly less frequent than with radical prostatectomy, nerve damage from thermal dispersion can cause temporary or permanent reduction in erectile quality, particularly if the tumour lies close to the neurovascular bundle.
- Rectourethral fistula: A rare but serious complication where an abnormal channel forms between the rectum and urinary tract. With modern continuous cooling systems and real-time safety monitoring, this occurs in fewer than 1% of primary HIFU cases, though risk is slightly higher in salvage cases following prior radiotherapy.
How to choose a specialist urology centre in Turkey and key questions to ask
Undergoing prostate ablation abroad requires thorough verification of clinical standards. Ensure your chosen facility has dedicated uro-oncology specialists who perform focal therapy regularly rather than occasionally. The hospital should feature modern 3-Tesla multiparametric MRI, fusion-guided biopsy systems, and high-definition robotic HIFU consoles. High-standard centres conduct multidisciplinary tumour board meetings where urologists, oncologists, and radiologists review your imaging together before recommending an intervention, coordinated through hospital departments offering oncology treatments in Turkey.
Red flags include clinics that promise a guaranteed cure with zero complications, surgeons who suggest HIFU for advanced or metastatic cancer, providers who do not perform pre-treatment MRI fusion planning, and facilities that lack a clear follow-up protocol for post-discharge PSA monitoring. Submit your multiparametric MRI scans and biopsy reports through our free quote page for an initial multidisciplinary evaluation.
Essential questions to ask during your consultation include:
- How many HIFU prostate ablations has the lead urologist performed using this specific robotic system?
- Does my pre-operative MRI and biopsy profile indicate unifocal, unilateral, or bilateral disease?
- What safety margins will be maintained around the neurovascular bundle and urinary sphincter in my case?
- How many days will I need to keep the urinary catheter, and will it be removed before I fly home?
- What structured PSA testing and MRI schedule do you recommend after I return to my home country?
- What emergency protocols and specialist contacts are available if I experience urinary retention after catheter removal?
Hospitals with Oncology in Turkey
Frequently asked questions
HIFU, or high-intensity focused ultrasound, is a minimally invasive treatment for localised prostate cancer. It uses precise, focused sound waves delivered via a transrectal probe to heat and destroy cancerous tissue within the prostate gland. Because the acoustic beams converge on targeted lesions, surrounding structures like the urinary sphincter and erectile nerves can often be preserved.
Clinical studies show that HIFU delivers reliable short-to-medium-term cancer control for men with localised, low- to intermediate-risk prostate cancer. It achieves disease eradication in targeted areas with significantly lower rates of incontinence and impotence than radical surgery. However, patients require regular monitoring with PSA tests and MRI scans, as long-term comparative data beyond 10 years are still developing.
In Turkey, HIFU treatment generally costs between €5,500 and €12,000, depending on whether focal ablation or hemi-gland treatment is required. By comparison, private treatment in the UK or Germany typically ranges from €10,000 to €22,000. Comprehensive Turkish hospital packages usually cover pre-operative imaging reviews, the hospital stay, surgeon fees, catheter supplies and airport transfers.
Unlike cosmetic procedures, outcomes are measured oncologically and functionally rather than visually. Before treatment, patients have biopsy-confirmed localised tumours. After HIFU, success is marked by a sharp drop in PSA to a low nadir, clear post-treatment MRI scans, and negative follow-up biopsies, alongside preservation of urinary continence and, in most cases, baseline erectile function.
Initial recovery involves wearing a temporary urinary catheter for five to fourteen days while post-treatment tissue swelling settles. Most men resume light desk work within one to two weeks once the catheter is removed. Strenuous exercise, heavy lifting, cycling and sexual activity should be avoided for three to four weeks to allow internal tissues to heal.
The procedure itself is performed under general anaesthesia or spinal anaesthesia, so you feel no discomfort during ablation. Afterwards, most patients experience mild perineal aching, pelvic fullness, or bladder spasms from the catheter. These symptoms are generally mild and easily managed with standard oral analgesics and anti-inflammatory medication during the first few days.
When successful, HIFU permanently destroys the targeted prostate tumour cells. Five- to ten-year data demonstrate good disease-free survival in well-selected patients with organ-confined disease. However, because remaining prostate tissue is left intact, ongoing annual PSA testing and periodic MRI monitoring are essential to detect any new or recurrent lesions early.
HIFU is recognised by international urological guidelines as a safe, organ-preserving procedure for selected patients. Major complications are rare when performed by experienced urologists using real-time ultrasound and MRI fusion. Serious risks like rectourethral fistula occur in less than one percent of cases, though temporary catheterisation and transient urinary symptoms are expected.
Radical prostatectomy removes the entire prostate gland, providing definitive histology but carrying higher risks of permanent urinary leakage and erectile dysfunction. HIFU offers targeted destruction of cancerous zones with a much lower impact on sexual and urinary quality of life, making it attractive for localised, non-aggressive tumours, though repeat treatment may occasionally be needed.
Patients typically spend five to seven nights in Turkey. This includes admission the morning of surgery, an overnight hospital stay, and four to five days at a nearby hotel. Before flying home, you will attend a follow-up consultation with your urologist for examination, catheter evaluation or removal, and travel clearance.
Patient stories